At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Donepezil 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients With Mild Alzheimer's Disease Treated With Donepezil
In Brief
A Phase 2 clinical trial evaluating Placebo and Donepezil for Alzheimer's Disease. Completed, enrolled 36 participants.
Detailed Summary
This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD. The primary hypothesis is that for one of the Cogstate battery tests, One Card Learning (OCL), the standard deviation associated with the change from baseline in OCL measurements after 12 weeks of donepezil and placebo treatments is =\<0.1
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartApr 2014
Primary CompletionJul 2016
TodayJul 2026
First PostedFeb 17, 2014
Enrollment StartApr 22, 2014
Primary CompletionJul 13, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.4 years ago
Interventions
Placebodrug
Placebo for donepezil hydrochloride capsule
Donepezildrug
5 mg donepezil hydrochloride capsule.
Donepezildrug
10 mg donepezil hydrochloride capsule.